Camelids Single Domain Antibody Development
Single domain antibodies are a type of antibody fragment that are smaller in size compared to traditional antibodies. They are derived from heavy-chain antibodies found in camelids (alpaca and llama etc.) and other animals, and their compact size makes them particularly useful in applications where size is a limiting factor, such as imaging, drug delivery, and therapeutic applications. Combining our SMab™ platform with phase display technology coupled with large scale screening has enabled Yurogen to develop Single domain antibodies with great diversity, specificity, and affinity with short turnaround time.
Dual PlatformProprietary Smab platform plus phage display platform used to improve diversity
Proprietary AlgorithmNGS sequencing combined with proprietary algorithm to dig out rare VHH sequence
Unique ImmunizationExpertise in DNA Immunization and cell membrane extract immunization
Multiple Expression HostChoice of E.Coli, Pichia pastoris, and mammalian expression system
Reliable Animal SourceUSDA certified animal farm & guaranteed naive llamas without immune background
Professional Support TeamPhD. level scientists provide tailored technical support & customer service
- Phase I: Immunization
- Phase II: : SMab™ or phage display platform Screening for VHH
- Phase III: VHH expression and purification
Platform | Phase | Service | Description | Timeline | | Phase I | Immunization |
- Standard Package: Immunize ONE llama or alpaca for 6-9 weeks with 4 injections and 3 bleed collections
- Bleed titer and blocking measured with ELISA for IgG2/3 and total IgG
- (Optional) Additional Assays: counter screen ELISA & FACS etc.
- PBMC isolation
- Phase I report
| 6-9 weeks |
SMab™ Platform | Phase IIa | Llama Single B cell Sorting |
- Antigen and IgG2/3 double specific llama B cell sorting & culture
- High throughput ELISA screening for cultured supernatant
- Freeze the cell pallet for selected ELISA positive clones
- Further function assay for the supernatant of positive clones
| 2 weeks |
Phase IIb | VHH cloning & LEM Construction |
- Amplification of VHH genes from selected positive clones
- Construction of Linear Expression Module (LEM) (Optional)
- HEK293 cells transfected with LEM for recombinant expression and further functional assay (Optional)
| 2-3 weeks |
Phage Display Platform | Phase IIa | Phage Display Library Construction |
- VHH phage display library construction
- VHH phage display library QC, including
- The diversity of library: > 108 cfu
- The size of library: > 1011 cfu
- VHH insert rate: > 95%
| 4 weeks |
Phase IIb | Library Screen & Sequencing of positive clone |
- Enrichment of antigen-specific phages (2 or 3 cycles)
- Pick up to 4 X 96 binders for further phage ELISA primary and secondary screening
- Sanger sequencing of ELISA positive phages for VHH gene
- Perform next-generation sequencing (NGS) for all enriched phages; positive candidates recommendation with Proprietary unique Algorithm (optional)
| 4 weeks |